Literature DB >> 17302896

Activated T cell subsets in human type 1 diabetes: evidence for expansion of the DR+ CD30+ subpopulation in new-onset disease.

C Baker1, L Chang, K A Elsegood, A J Bishop, D H Gannon, P Narendran, N J Leech, C M Dayan.   

Abstract

An important limitation in T cell studies of human autoimmune (type 1) diabetes is lack of direct access to cells infiltrating the pancreas. We hypothesized that cells recently released from the pancreas into the blood might express a characteristic combination of markers of activation. We therefore examined the recently activated circulating T cell population [CD3+, human leucocyte antigen D-related (HLA-DR+)] using cytokine production and 10 additional subset markers [CD69, CD25, CD122, CD30, CD44v6, CD57, CD71, CCR3 (CD193), CCR5 (CD195) or CXCR3 (CD183)], comparing newly diagnosed adult (ND) (age 18-40 years) patients (n=19) to patients with diabetes for >10 years [long-standing (LS), n=19] and HLA-matched controls (C, n=16). CD3+ DR+ cells were enriched by two-step immunomagnetic separation. No differences in basal or stimulated production of interleukin (IL)-4, IL-10, IL-13 or interferon (IFN)-gamma by CD3+ DR+ enriched cells were observed between the different groups of subjects. However, among the CD3+ DR+ population, significant expansions appeared to be present in the very small CD30+, CD69+ and CD122+ subpopulations. A confirmatory study was then performed using new subjects (ND=26, LS=15), three-colour flow cytometry, unseparated cells and three additional subset markers (CD38, CD134, CD4/CD25). This confirmed the expansion of the CD3+ DR+ CD30+ subpopulation in ND subjects. We conclude that a relative expansion in the T cell subpopulation with the activated phenotype CD3+ DR+ CD30+ is seen in the peripheral blood of subjects with newly diagnosed type 1 diabetes. This subpopulation represents less than 0 x 7% of circulating T cells and may provide a rich source of disease-specific T cells that can be isolated from blood.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17302896      PMCID: PMC1810485          DOI: 10.1111/j.1365-2249.2006.03307.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  48 in total

Review 1.  The role of CD30 in atopic disease.

Authors:  A Bengtsson
Journal:  Allergy       Date:  2001-07       Impact factor: 13.146

2.  Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

Authors:  Kevan C Herold; William Hagopian; Julie A Auger; Ena Poumian-Ruiz; Lesley Taylor; David Donaldson; Stephen E Gitelman; David M Harlan; Danlin Xu; Robert A Zivin; Jeffrey A Bluestone
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

3.  CD30 expression identifies the predominant proliferating T lymphocyte population in human alloimmune responses.

Authors:  Keith W Chan; Corwyn D Hopke; Sheri M Krams; Olivia M Martinez
Journal:  J Immunol       Date:  2002-08-15       Impact factor: 5.422

4.  Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood.

Authors:  Jacqueline D Trudeau; Carolyn Kelly-Smith; C Bruce Verchere; John F Elliott; Jan P Dutz; Diane T Finegood; Pere Santamaria; Rusung Tan
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 5.  Type 1 diabetes: new perspectives on disease pathogenesis and treatment.

Authors:  M A Atkinson; G S Eisenbarth
Journal:  Lancet       Date:  2001-07-21       Impact factor: 79.321

6.  Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial.

Authors:  I Raz; D Elias; A Avron; M Tamir; M Metzger; I R Cohen
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

Review 7.  Update on major trials for the prevention of type 1 diabetes mellitus: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT).

Authors:  D A Schatz; P J Bingley
Journal:  J Pediatr Endocrinol Metab       Date:  2001       Impact factor: 1.634

8.  Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects.

Authors:  Helena Reijonen; Erik J Novak; Sharon Kochik; Anne Heninger; Andrew W Liu; William W Kwok; Gerald T Nepom
Journal:  Diabetes       Date:  2002-05       Impact factor: 9.461

Review 9.  Autoreactive T cells in endocrine/organ-specific autoimmunity: why has progress been so slow?

Authors:  Bart O Roep
Journal:  Springer Semin Immunopathol       Date:  2002-12

10.  Diversity and dynamics of the T-cell response to MBP in DR2+ve individuals.

Authors:  G Mazza; M Ponsford; P Lowrey; M J Campbell; J Zajicek; D C Wraith
Journal:  Clin Exp Immunol       Date:  2002-06       Impact factor: 4.330

View more
  8 in total

1.  Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.

Authors:  K A Blum; S-H Jung; J L Johnson; T S Lin; E D Hsi; D M Lucas; J C Byrd; B D Cheson; N L Bartlett
Journal:  Ann Oncol       Date:  2010-04-27       Impact factor: 32.976

2.  3DFAACTS-SNP: using regulatory T cell-specific epigenomics data to uncover candidate mechanisms of type 1 diabetes (T1D) risk.

Authors:  Ning Liu; Timothy Sadlon; James Breen; Simon C Barry; Ying Y Wong; Stephen Pederson
Journal:  Epigenetics Chromatin       Date:  2022-06-30       Impact factor: 5.465

3.  An alternative role for Foxp3 as an effector T cell regulator controlled through CD40.

Authors:  Gisela M Vaitaitis; Jessica R Carter; Dan M Waid; Michael H Olmstead; David H Wagner
Journal:  J Immunol       Date:  2013-06-17       Impact factor: 5.422

4.  Reduction of specific circulating lymphocyte populations with metabolic risk factors in patients at risk to develop type 2 diabetes.

Authors:  Helena Cucak; Dorte Vistisen; Daniel Witte; Annelotte Philipsen; Alexander Rosendahl
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

5.  Decreased CD127 expression on CD4+ T-cells and elevated frequencies of CD4+CD25+CD127- T-cells in children with long-lasting type 1 diabetes.

Authors:  Marcin Moniuszko; Barbara Glowinska-Olszewska; Malgorzata Rusak; Marta Jeznach; Kamil Grubczak; Danuta Lipinska; Robert Milewski; Anna Justyna Milewska; Milena Dabrowska; Ewa Jablonska; Adam Kretowski; Maria Gorska; Anna Bodzenta-Lukaszyk; Artur Bossowski
Journal:  Clin Dev Immunol       Date:  2013-11-21

6.  Overproduction of CXC chemokines CXCL1, CXCL9, CXCL10 and CXCL12 in β-thalassemia major or patients.

Authors:  Hamid Najmaddini; Gholamhossein Hassanshahi; Hamid Ostadebrahimi; Hoda Barkhordari; Habibeh Mashayekhi; Mina Nazari; Mozhgan Moogooei; Yassin Safari Arababadi; Fatemeh Peighambari; Mojgan Noroozi Karimabad
Journal:  Ann Saudi Med       Date:  2014 Mar-Apr       Impact factor: 1.526

7.  Phenotypic Analysis of Human Lymph Nodes in Subjects With New-Onset Type 1 Diabetes and Healthy Individuals by Flow Cytometry.

Authors:  Jennie H M Yang; Leena Khatri; Marius Mickunas; Evangelia Williams; Danijela Tatovic; Mohammad Alhadj Ali; Philippa Young; Penelope Moyle; Vishal Sahni; Ryan Wang; Rejbinder Kaur; Gillian M Tannahill; Andrew R Beaton; Danielle M Gerlag; Caroline O S Savage; Antonella Napolitano Rosen; Frank Waldron-Lynch; Colin M Dayan; Timothy I M Tree
Journal:  Front Immunol       Date:  2019-10-31       Impact factor: 7.561

8.  Analysis of immune cell components and immune-related gene expression profiles in peripheral blood of patients with type 1 diabetes mellitus.

Authors:  Jian Lin; Yuanhua Lu; Bizhou Wang; Ping Jiao; Jie Ma
Journal:  J Transl Med       Date:  2021-07-26       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.